Jasper Therapeutics to Present at Upcoming Conferences
March 09, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to...
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update
March 08, 2023 16:05 ET
|
Jasper Therapeutics
Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous UrticariaPresentation of Key Briquilimab Clinical Data, Including Initial Results in...
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors
February 17, 2023 08:20 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
February 17, 2023 08:10 ET
|
Jasper Therapeutics
Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved through six months for the first patient...
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
February 17, 2023 08:00 ET
|
Jasper Therapeutics
Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil engraftment at a median of 19 days after conditioning with...
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients
February 16, 2023 16:05 ET
|
Jasper Therapeutics
First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-upThird sickle cell disease participant has now achieved 100% donor myeloid chimerism...
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023 16:05 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023
January 30, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 27, 2023 13:10 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
January 25, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...